Shots:

• involves assessing of Tecentriq + CT vs CT as monothx. in 1-213 patients with previously untreated LA or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy
• The P-III IMvigor130 study results: mPFS (8.2 vs 6.3mos.); median OS (16.0 vs 13.4 mos.); ORR (47.4% vs 43.8%); safety data of combination therapy is consistent with the safety profile of Tecentriq with no new safety signals
• Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1receptors- currently being evaluated in 4 P-III studies in combination with other therapies for early and advanced bladder cancer

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche